Sugi Predict

Sugi Predict / Compounds / SCHEMBL1247509

SCHEMBL1247509

SCHEMBL1247509

O=C1NC(=S)S/C1=C/c1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAT1 P18440 5/20 1.00
▸ CA2 P00918 1/20 0.82
▸ EPHX1 P07099 1/20 0.82
▸ MMP3 P08254 2/20 0.72
▸ MMP13 P45452 2/20 0.72
▸ MYC P01106 3/20 0.68
▸ CISD1 Q9NZ45 3/20 0.68
▸ MAX P61244 2/20 0.68
▸ IL1RN P18510 1/20 0.67
▸ ERAP1 Q9NZ08 1/20 0.67
▸ PIM1 P11309 2/20 0.65
▸ RAB9A P51151 2/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ MAOA P21397 1/20 0.63
▸ PIM3 Q86V86 1/20 0.63
▸ PIM2 Q9P1W9 1/20 0.63
▸ NPC1 O15118 1/20 0.62
▸ CRHBP P24387 1/20 0.62
▸ CRHR2 Q13324 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10596480 1.00 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL1247510 1.00 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL1812224 0.90 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL3491175 0.90 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL4416451 0.90 NAT1 (1.00) NAT1CA2EPHX1MMP3MMP13
SCHEMBL12891790 0.87 PIM1 (0.83) NAT1CA2CISD1PIM1RAB9A
SCHEMBL1248782 0.87 PIM1 (0.83) NAT1CA2CISD1PIM1RAB9A
SCHEMBL1248780 0.87 PIM1 (0.83) NAT1CA2CISD1PIM1RAB9A
SCHEMBL19991267 0.87 NAT1 (0.76) NAT1CA2EPHX1MMP3MMP13
SCHEMBL18102890 0.87 NAT1 (0.76) NAT1CA2EPHX1MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002062337-A1 THIAZOLIDINEDIONES SMITHKLINE BEECHAM CORPORATION (US) 2002-08-15 — — WO claimed
EP-0915090-A1 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1999-05-12 — — EP claimed
US-5523314-A RHODANINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-06-04 — — US claimed
EP-0587377-A2 Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1994-03-16 — — EP claimed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 — — US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 — — US disclosed
EP-1585541-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-11-14 — — EP disclosed
EP-1429763-B1 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-05-30 — — EP disclosed
EP-1768694-A1 PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN NOVO NORDISK A/S (DK) 2007-04-04 — — EP disclosed
US-20060258561-A1 Novel NPH insulin preparations NOVO NORDISK A/S (DK) 2006-11-16 — — US disclosed
WO-2006082245-A1 PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed
US-20060069013-A1 Pharmaceutical preparations comprising acid-stabilised insulin NOVO NORDISK A/S (DK) 2006-03-30 — — US disclosed
WO-2004056347-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-07-08 — — WO disclosed
EP-1429763-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2004-06-23 — — EP disclosed
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer NOVO NORDISK A/S (DK) 2003-12-11 — — US disclosed
WO-2003027081-A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK A/S (DK) 2003-04-03 — — WO disclosed
WO-2002062337-A1 THIAZOLIDINEDIONES SMITHKLINE BEECHAM CORPORATION (US) 2002-08-15 — — WO disclosed
EP-0915090-A1 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1999-05-12 — — EP disclosed
US-5523314-A RHODANINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-06-04 — — US disclosed
EP-0587377-A2 Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1994-03-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258561-A1 Novel NPH insulin preparations IAPP, HBB, INSR NAT1 2886/4885CA2 3796/4885EPHX1 4049/4885
US-20060069013-A1 Pharmaceutical preparations comprising acid-stabilised insulin IAPP, GPR119, INSR NAT1 4021/4885CA2 2795/4885EPHX1 4373/4885
US-20030229120-A1 Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer IAPP, IRS1, GPR119 NAT1 4334/4885CA2 3456/4885EPHX1 4571/4885
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand IAPP, IRS1, HBB NAT1 4542/4885CA2 4342/4885EPHX1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.